Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Group 1 - Abeona Therapeutics Inc. will participate in several investor conferences in September 2024, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, and Cantor Global Healthcare Conference [1] - The company will present its investigational autologous, COL7A1 gene-corrected epidermal sheets, known as prademagene zamikeracel (pz-cel), which is currently in development for recessive dystrophic epidermolysis bullosa [2] - Abeona's manufacturing facility is fully integrated and capable of supporting commercial production of pz-cel upon FDA approval, and it has a portfolio of AAV-based gene therapies for ophthalmic diseases [2]